Welcome to our dedicated page for Gyre Therapeutics SEC filings (Ticker: GYRE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Gyre Therapeutics, Inc. (GYRE) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Gyre is a Nasdaq-listed biopharmaceutical issuer focused on fibrosis-first therapies, including Hydronidone for liver fibrosis and a commercial and development platform in the PRC through Gyre Pharmaceuticals. Its filings provide structured insight into financial performance, clinical and regulatory progress, capital-raising activities and corporate governance.
Investors can use this page to access Gyre’s current and historical reports, including Form 8-K filings that announce quarterly and year-to-date financial results, business updates, leadership changes and board appointments. Recent 8-Ks have covered earnings press releases, the appointment of an interim chief executive officer, the addition of a new director to the board and the filing of updated corporate presentations. Filings related to public offerings detail the terms of common stock issuances under an effective shelf registration statement, including gross proceeds and intended use of funds for Hydronidone Phase 2 development in MASH-associated liver fibrosis, research and development, manufacturing scale-up and general corporate purposes.
On Stock Titan, Gyre’s 10-K annual reports and 10-Q quarterly reports, when available, can be paired with AI-powered summaries that explain key sections such as revenue drivers from ETUARY, Etorel and Contiva in the PRC, research and development spending on Hydronidone and other pipeline assets, and risk factor disclosures tied to clinical, regulatory and market conditions. Form 4 insider transaction reports, if filed, can be reviewed to see equity awards or share transactions by directors and officers mentioned in Gyre’s governance filings.
Each new GYRE filing is captured from the SEC’s EDGAR system and presented with tools to help interpret complex documents, including AI-generated highlights of important items, identification of material events and links to related press releases. This allows users to follow how Gyre’s fibrosis-focused strategy, China-based commercial operations and U.S. clinical plans are reflected in its official regulatory record.
Gyre Therapeutics, Inc. reported Q1 2026 revenue of $22.5 million, slightly above $22.1 million a year earlier, driven mainly by ETUARY, which contributed $21.0 million, or 93.1% of product sales. Newer products Contiva and Etorel added modest but growing contributions.
The company posted a net loss of $9.9 million, compared with net income of $3.7 million in Q1 2025, as selling, R&D, G&A and $2.6 million of transaction costs lifted operating expenses to $31.9 million. Despite the loss, operating cash flow was positive at $3.2 million, and cash and cash equivalents were $37.5 million as of March 31, 2026.
Total assets were $162.0 million and equity $137.0 million. Gyre’s China subsidiary remained the sole revenue source, while U.S. operations focused on Hydronidone development. After quarter-end, Gyre closed an all‑stock acquisition of Cullgen valued at approximately $300 million, bringing a new pipeline under common control accounting.
GYRE Therapeutics, Inc. Chief Executive Officer Luo Ying reported indirect open-market sales of company common stock held by a spouse. On May 5–6, 2026, a total of 10,315 shares of common stock were sold in two transactions at weighted average prices of $8.01 and $8.04 per share. The sales were executed pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2025, indicating they were pre-arranged. Following these transactions, indirect holdings reported as owned through the spouse totaled 2,565,226 shares of common stock.
Gyre Therapeutics, Inc. executive Joshua Benjamin Bergmann, the company’s GC and Corporate Secretary, reported his initial ownership of a stock option in a Form 3 filing. The option gives him the right to buy 47,530 shares of common stock at an exercise price of $8.09 per share.
According to the filing, the option expires on February 27, 2036. One quarter of the option will vest on June 16, 2026, and the remaining three quarters will vest in equal monthly installments over the following three years, as long as he continues serving the company on each vesting date.
GYRE THERAPEUTICS, INC. executive vice president and general manager Jialiang Wang has reported initial holdings of stock options for the company’s common stock. The Form 3 shows options covering 47,530 underlying shares at an exercise price of $5.98 per share expiring on November 12, 2034, 42,777 underlying shares at $2.00 expiring on April 16, 2031, 38,024 underlying shares at $0.93 expiring on January 12, 2030, and 95,060 underlying shares at $0.32 expiring on June 7, 2028, all held directly. A footnote states that one of these options is fully vested, while another vests over time starting on November 13, 2025, subject to continued service.
GYRE THERAPEUTICS, INC. Chief Scientific Officer Xiong Yue reports initial ownership of 2,376,500 shares of Series B Preferred Stock. These shares were received in the merger where a Gyre subsidiary combined with Cullgen Inc., with Cullgen becoming a wholly owned subsidiary effective as of May 4, 2026.
Each share of Series B Preferred Stock will be convertible, following stockholder approval and subject to a Beneficial Ownership Limitation, into five shares of common stock. The Series B Preferred Stock has no expiration date.
GYRE THERAPEUTICS, INC. chief executive officer Luo Ying filed a Form 3 that lists existing equity holdings in the company. The filing shows indirect ownership through a spouse of 2,575,541 shares of common stock, plus multiple stock option awards held both directly and indirectly with exercise prices between $0.32 and $5.98 and expirations from 2028 through 2034.
Gyre Therapeutics investors Songjiang Ma and Yueying Zhu report beneficial ownership of 7,342,131 shares, representing 6.33% of the company’s common stock. Their stake consists of 4,536,047 shares underlying options held by Mr. Ma that are exercisable within 60 days and 2,806,084 shares held directly by Ms. Zhu. The amendment is triggered by a change in Gyre’s shares outstanding following its all-stock acquisition of Cullgen Inc., which was valued at approximately $300 million and added 14,450,527 new shares. Ma and Zhu did not receive additional Gyre securities in the merger. The deal includes Series B Preferred Stock convertible into common shares, subject to a 19.99% issuance cap until stockholders vote on a Conversion Proposal at a meeting scheduled for June 10, 2026.
Ying Luo and Ping Lan report beneficial ownership of 10,211,387 shares of Gyre Therapeutics common stock, representing 8.6% of the class. This includes 5,373,091 shares underlying Mr. Luo’s options, 2,575,541 shares held directly by Ms. Lan, and 2,262,755 shares underlying Ms. Lan’s options, all exercisable within 60 days.
The amendment reflects Gyre’s all‑stock acquisition of Cullgen Inc., which valued Cullgen at approximately $300 million and added 14,450,527 Gyre common shares issued in the merger. Cullgen holders received either common stock or Series B Preferred Stock, each preferred share being convertible into five common shares after stockholder approval of a Conversion Proposal, subject to a 19.99% cap and individual beneficial ownership limits.
Series B Preferred Stock carries voting rights and dividend participation similar to common stock and is subject to protective provisions until conversion is approved. Certain executives, directors and stockholders entered lock‑up agreements restricting transfers of one‑third of their shares for 180 days, one‑third for 12 months and one‑third for 18 months after closing. A registration rights agreement requires Gyre to file a resale registration statement for Cullgen holders’ shares and related conversion shares within 45 days of closing and to use reasonable best efforts to have it declared effective within specified timeframes.
GNI USA, Inc. and GNI Group Ltd. report beneficial ownership of 86,323,015 shares of Gyre Therapeutics common stock, representing 69.1% of the company’s equity on an as-converted basis. This stake includes issued common shares plus stock underlying Series X and Series B preferred shares.
The filing reflects Gyre’s all-stock acquisition of Cullgen Inc., which valued Cullgen at approximately $300 million and closed on May 4, 2026. Cullgen shareholders received a mix of Gyre common stock and Series B Preferred Stock, each Series B share being convertible into five common shares once stockholders approve a Conversion Proposal.
The Series B Preferred Stock carries dividend and voting rights aligned with common stock, but key corporate actions affecting these preferred shares require approval from their holders until conversion is approved. Certain executives, directors and stockholders are subject to lock-up agreements that restrict transfers of portions of their holdings for 180 days, 12 months and 18 months after closing, and a registration rights agreement requires Gyre to file a resale registration statement for Cullgen holders.
GYRE THERAPEUTICS, INC. disclosed that GNI Group Ltd. and GNI USA, Inc., each a ten percent owner, received Series B Preferred Stock in connection with Gyre’s merger with Cullgen Inc., which became a wholly-owned subsidiary effective May 4, 2026.
GNI Group Ltd. holds 2,143,706 shares of Series B Preferred Stock, representing 10,718,530 underlying common shares, and GNI USA holds 458,120 shares, representing 2,290,600 underlying common shares. Each preferred share will be convertible into five common shares following stockholder approval, subject to a Beneficial Ownership Limitation, and the Series B Preferred Stock has no expiration date.